Efficacy of Zoledronic Acid in Patients with Systemic Osteoporosis and Problem of «Non Respondents» to the Treatment


Cite item

Full Text

Abstract

Prospective study of zolendronic acid efficacy was performed in 112 patients with systemic osteoporosis. Study results confirmed the presence of patients who did not response to the treatment: in 15.7 % of observations reduction of mineral bone density (BMD) continued to progress. No significant differences in initial deviations of resorption and bone formation markers, peculiarities of calcium homeostasis were detected in “non respondents”. At the same time by the 12th month after treatment initiation the relationship between BMD increase with preservation of marked decrease of resorption marker (deoxypyridinoline) and bone formation marker (osteocalcin) was noted, that pointed out the expediency of prognostic model creation. Evaluation of the influence of certain risk factors (age, results of blood and urine biochemical tests, data of densitometry including the results of femoral neck BMD in some patients) using discriminant analysis showed that 81.5% of patients were correctly referred to the groups of patients who responded and not responded to treatment. Out of all initially studied parameters the most significant were 7 that in 78.6% of cases (method sensitivity) enabled to identify the patients with negative treatment effect and in 82.1% of cases (method specificity) - with positive treatment effect.

About the authors

S. S Rodionova

Central Institute of Traumatology and Orthopaedics named after N.N. Priorov, Moscow, Russia

Email: rod06@inbox.ru
доктор мед. наук, профессор, рук. Центра остеопороза ЦИТО им. Н.Н. Приорова; Тел.: +7 (495) 601-44-07. 127299, Москва, ул. Приорова, д. 10

Yu. V Buklemishev

Central Institute of Traumatology and Orthopaedics named after N.N. Priorov, Moscow, Russia

врач травматолог-ортопед, науч. сотр. Центра остеопороза

References

  1. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., Adachi J.D., Pieper C.F. , Mautalen C. et al. HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. N. Engl. J. Med. 2007; 357: 1799-809.
  2. Arabmotlagh M., Rittmeister M., Hennigs T. Alendronate prevents femoral periprosthetic bone loss following total hip arthroplasty: prospective randomized double-blind study. J. Orthop. Res. 2006; 24 (7): 1336-41.
  3. Hilding M., Aspenberg P. Postoperative clodronate decreases prosthetic migration: 4-year follow-up of a randomized radiostereometric study of 50 total knee patients. Acta Orthop. 2006; 77: 912-6.
  4. Thillemann T.M., Pedersen A.B., Mehnert F., Johnsen S.P., Soballe K. Postoperative use of bisphosphonates and risk of revision after primary total hip arthroplasty: a nationwide population-based study. Bone. 2010; 46: 946-51.
  5. Prieto-Alhambra D., Javaid, K., Judge M., Murray A., Carr D., Cooper A., Arden C., Nigel K. Association between bisphosphonate use and implant survival after primary total arthroplasty of the knee or hip: population based retrospective cohort study. BMJ. 2011; 343: d7222.
  6. Delmas P.D. The use of bisphosphonates in the treatments of osteoporosis. Curr. Opin. Rheumatol. 2005; 17 (4): 462-6.
  7. Black D.M., Delmas P.D., Eastell R., Reid I.R., Boonen S., Cauley J.A. et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med. 2007; 356 (18): 1809-22.
  8. Nguyen T.V., Eisman J.A. Pharmacogenomics of osteoporosis: opportunities and challenges. J. Musculoskelet. Neuronal. Interact. 2006; 6 (1): 62-72.
  9. Massart F.L., Brandi M.L. Genetics of the bone response to bisphosphonate treatments. Clin. Cases Miner. Bone Metab. 2009; 6 (1): 50-4.
  10. Гланц С. Медико-биологическая статистика. М.: Практика; 1998.
  11. Наследов А. SPSS 15. Профессиональный статистический анализ данных. СПб: Издательский дом «Питер»; 2011.
  12. Boonen S., Reginter J.-Y., Kaufman J.-M., Lippuner K., Zanchetta J., Langdah B. et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N. Engl. J. Med. 2012; 367: 1714-23.
  13. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., Kainberger F., Kässmann H., Piswanger-Sölkner J-С. et al. Austrian Breast and Colorectal Cancer Study Group (ABCSG). Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008; 9 (9): 840-9.
  14. Reid D., Delmas P. The Addition of once-yearly zoledronik acid 5 mg to non bisphosphonate treatment for osteoporosis reduce fractures in postmenopausal women: The HORIZONT PFT. 19h Annual Meeting. Orlando. USA. 2008: 36-7.
  15. Якушевская О.В., Бордакова Е.В., Гависова А.А., Кузнецов С.Ю., Юренева С.В., Иванец Т.Ю. и др. Влияние золедроновой кислоты и ибандроната на костный метаболизм у женщин с постменопаузальным остеопорозом. Остеопороз и остеопатии. 2012; 2: 21-4.
  16. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr. Pharm. Des. 2003; 9: 2643-58.
  17. Sorscher S.M. Electrolyte abnormalities with zoledronic acid therapy. Cancer J. 2002; 8 (4): 348-9.
  18. Nordin B.E., Morris H.A. Osteoporosis and vitamin D. J. Cell. Biochem. 1992; 49 (1): 19-25.
  19. Nuti R., Bianchi G., Brandi M.L. Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatol. Int. 2006; 26 (5): 445-53.
  20. Richy F., Schacht E., Bruyere O. Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: A comparative meta-analysis. Calcif. Tissue. Int. 2005; 76: 176-86.
  21. Родионова С.С., Еловой-Вронский А.А., Бернакевич А.И. Альфакальцидол или колекальциферол в комбинации с ибандроновой кислотой при лечении постменопаузального системного остеопороза. Остеопороз и остеопатии. 2014; 1: 21-4.
  22. Corral-Gudino L., del Pino-Montes J., García-Aparicio J. et al. -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone. Bone. 2006; 38: 589-94.
  23. Massart F. Human races and pharmacogenomics of effective bone treatments. Gynecol. Endocrinol. 2005; 20 (1): 36-44.

Copyright (c) 2015 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies